CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
IPO Year: 1997
Exchange: AMEX
Website: cel-sci.com
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
4 - CEL SCI CORP (0000725363) (Issuer)
Fastest customizable press release news feed in the world
Patient enrollment expected to commence at clinical centers in the U.S., Europe, Asia and later on in South America The 212-patient confirmatory study is powered at approximately 97% to confirm a previously observed 0.34 hazard ratio, representing a 66% reduction in the risk of death In the target population, Multikine followed by standard of care increased the 5-year survival rate to 73% versus 45% with standard of care alone Pre-surgical tumor responses will be assessed and may serve as the basis for an early conditional or accelerated approval application with the FDA CEL-SCI Corporation (NYSE:CVM) today announced it is launching its global Confirmatory Registration Study of
Ceremony highlights shared commitment to oncology innovation, healthcare advancement, and international collaboration Strategic partnership spans regulatory, marketing, distribution, and revenue sharing agreement for Multikine® in the treatment of head and neck cancer in Saudi Arabia with option to extend to Gulf Cooperation Council countries CEL-SCI Corporation (NYSE:CVM) today announced the successful conclusion of a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 on June 22nd in San Diego, marking a significant step forward in U.S.–Saudi cooperation in healthcare innovation and oncology. This press release features multimedia. View t
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts offering of 2,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $2.5 million.The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital.ThinkEquity acted as the sole placement agent for the offering.The securities were offered and sold pursuant to a
U.S. Confirmatory Registration Study expected to begin Summer 2026 Multikine achieved a 73% five-year survival rate versus 45% for standard of care alone in the target patient population and improved quality of life Saudi partnership includes a 50%/50% net revenue share and supports potential patient access in one of the Middle East's largest oncology markets CEL-SCI Corporation (NYSE:CVM) today highlighted its dual-track strategy to bring Multikine® (Leukocyte Interleukin, Injection)* to patients with newly diagnosed locally advanced head and neck cancer through parallel regulatory initiatives in the U.S. and Saudi Arabia. The Company plans to commence its Confirmatory Registration
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts offering of 2,500,000 shares of common stock at an offering price of $1.00 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be $2.5 million. The offering is expected to close on June 16, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agent for the offering. Th
Saudi Arabia Emerges as a Global Biotech Investment Hub Under Vision 2030 Senior Saudi Government, Investment and Healthcare Leaders to Attend the CEL-SCI / Amarox Signing & Opening Ceremonies Strategic Agreement Marks Important Step Toward Commercialization of Multikine® in One of the Middle East's Fastest-Growing Healthcare Markets CEL-SCI Corporation (NYSE:CVM) today announced it will participate in a formal signing ceremony with Saudi Amarox ("Amarox") during the BIO International Convention 2026 in San Diego, California. The ceremony will mark an important milestone in advancing the previously announced strategic agreement between the companies focused on the commercialization an
On Track to Commence Pivotal Confirmatory Head and Neck Cancer Registration Study by Summer/Fall 2026 Signed Key Partnership with Amarox to Advance Multikine Approval and Commercialization in Saudi Arabia 50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation CEL-SCI's CEO continues to invest in the Company acquiring a cumulative ~$930,000 worth of stock over the past 10 months CEL-SCI Corporation (NYSE:CVM) today reported financial results for three months ended March 31, 2026, as well as key recent corporate, commercial, regulatory, and clinical developments for Multikine (Leukocyte Interleukin, Injection)*. "Durin
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the closing of its best-efforts public offering of 6,000,000 shares of its common stock. Each share of common stock was sold at a public offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, were approximately $7.2 million. The Company intends to use the net proceeds from the offering to fund the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering. A registration statement on
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent's fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital. ThinkEquity is acting as the sole placement agen
50%/50% revenue sharing agreement for Multikine sales in Saudi Arabia upon receipt of Breakthrough Medicine Designation Amarox to act as the local regulatory representative and lead all communications with the Saudi Food and Drug Authority (SFDA) Amarox ranked #1 for SFDA applications for critical and unavailable medicine for 3 consecutive years Amarox to be exclusive commercial distributor of Multikine in Saudi Arabia, upon SFDA approval, with optional expansion to GCC countries Immunotherapy is among the fastest-growing segments in the Saudi cancer market, projected to reach $2.7 billion by 2033 CEL-SCI Corporation (NYSE:CVM) today announced it has signed a strategic pa
DEF 14A - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
424B5 - CEL SCI CORP (0000725363) (Filer)
RW - CEL SCI CORP (0000725363) (Filer)
RW - CEL SCI CORP (0000725363) (Filer)
10-Q - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
8-K - CEL SCI CORP (0000725363) (Filer)
EFFECT - CEL SCI CORP (0000725363) (Filer)
S-1/A - CEL SCI CORP (0000725363) (Filer)
Live Leadership Updates
CEL-SCI Corporation (NYSE:CVM) today reported financial results for the quarter ended June 30, 2024, as well as key recent clinical and corporate developments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815767286/en/The table includes detailed results from the bias analysis. (Graphic: Business Wire) Clinical and Corporate Developments include: In July 2024, following the end of the third fiscal quarter, CEL-SCI reported the results of a bias analysis. The bias analysis, a standard process to ensure a trial's findings are reliable, was conducted in preparation for CEL-SCI's upcoming confirmatory Registration Study. This
CEL-SCI Corporation (NYSE:CVM) today announced that Robert ("Bob") Watson, who has served as a Director of the Company since 2017, has been appointed Chairperson of the Board. Bob is an accomplished business leader who began his career as an investment banker. With over four decades of experience across various healthcare markets, Bob brings extensive expertise in capital formation strategies and partnerships to drive an efficient capital structure. During his career as CEO or President of private and publicly traded companies in the healthcare sector, Bob negotiated over a half dozen exits and more than $750 million in capital transactions including IPOs, secondary offerings, and debt in
CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Mario Gobbo to its Board of Directors. Mr. Gobbo has nearly 40 years of banking and corporate finance experience in healthcare and energy. His expertise encompasses venture capital and private equity as well as investment banking and strategic advisory services. He has served as an officer or director for a number of companies including several biotech companies: Xcovery, Ocimum/Genelogic and Helix BioPharma. Prior to that, Mr. Gobbo worked in the financial industry for Lazard LLC, Swiss Bank Corporation, the European Bank for Reconstruction and Development, Natixis Bleichroeder, Inc., and International Finance Corporation
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch CEL-SCI Corporation (NYSE:CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors. Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the world's first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from t
This live feed shows all institutional transactions in real time.
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)
SC 13G/A - CEL SCI CORP (0000725363) (Subject)